<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this study is to examine the relationship of t(11;16)(q23;p13) to the type of <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> noted by hematopathology </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, t(11;16) has been reported in fewer than 20 patients, <z:hpo ids='HP_0000001'>all</z:hpo> with the diagnosis of therapy-related (secondary) <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (sAML) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Putative involved genes are the MLL on 11q23 and CBP at 16p13 </plain></SENT>
<SENT sid="3" pm="."><plain>Data from The University of Texas M </plain></SENT>
<SENT sid="4" pm="."><plain>D </plain></SENT>
<SENT sid="5" pm="."><plain>Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center (UTMDACC) Cytogenetics Laboratory revealed 3 patients with t(11;16) observed during the past 5 years </plain></SENT>
<SENT sid="6" pm="."><plain>Two of the patients had a prior diagnosis of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) and had been treated with chemotherapy, which included <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The other patient presented with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and no history of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> or chemotherapy </plain></SENT>
<SENT sid="8" pm="."><plain>Two of the 3 patients had t(11;16) as the sole cytogenetic abnormality </plain></SENT>
<SENT sid="9" pm="."><plain>One patient had a t(11;16) clone that included t(9;21) and t(10;21) as additional changes </plain></SENT>
<SENT sid="10" pm="."><plain>Translocation (11;16) has previously been reported only as being therapy-related </plain></SENT>
<SENT sid="11" pm="."><plain>In this study, the t(11;16) was seen in 2 patients with previous <z:hpo ids='HP_0002665'>lymphomas</z:hpo> treated with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (CHOP) </plain></SENT>
<SENT sid="12" pm="."><plain>A single patient with apparently de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> constitutes the first reported instance of non-treatment associated t(11;16) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>